Home Featured Page 113

Featured

Latest

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal...

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma...

Psychedelics Weekly – Research Explained: Ketamine and the Corticothalamic Network, Psilocybin...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Australia Recognises MDMA and Psilocybin as Medicines

A Spotlight on Psychedelic Research Methods

Panel: Psychedelic Research Methods

A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

Historical Insights on the Psychedelic Renaissance

1...112113114...303 Page 113 of 303

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your Truth

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal...

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma...

Psychedelics Weekly – Research Explained: Ketamine and the Corticothalamic Network, Psilocybin...

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development...

Australia Recognises MDMA and Psilocybin as Medicines

A Spotlight on Psychedelic Research Methods

Panel: Psychedelic Research Methods

A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

Historical Insights on the Psychedelic Renaissance

EDITOR PICKS

Michael Ryoshin Sapiro, PsyD – Truth Medicine, Psychedelics, and Living Your...

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY